RxDoctor Payments Data

Svetlana Yakov

Psychiatry · Billings, MTNPI 1992061618

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.1% of the total across 136 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,032 and has fallen 64.8% since, to $363 in 2025. Among psychiatry clinicians in MT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,375in general payments, 2019–2025

Across 136 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$368
  • AbbVie$361
  • Lundbeck LLC$283
  • Vanda Pharmaceuticals Inc.$261
  • Johnson & Johnson$261
  • Otsuka America Pharmaceutical, Inc.$228
  • plus $613 from 12 others

What the payments were for

  • Food & beverage$2,25995%
  • Education$1165%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,375 in reported general payments places this provider in the 90th percentile of 82 psychiatry providers in Montana.

See all psychiatry providers in Montana

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole11$14,552
Lurasidone Hcl13$1,528
Bupropion XlBupropion Hcl19$452
Memantine Hcl15$376
Quetiapine Fumarate18$309
Buspirone Hcl15$195
Lamotrigine25$186
Duloxetine Hcl11$145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$228$14,55211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 82 psychiatry providers in Montana.

Other psychiatry in Billings

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →